Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $3.00 by Analysts at HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO - Free Report) had its price target cut by HC Wainwright from $5.00 to $3.00 in a report issued on Monday,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company's stock.

INO has been the subject of several other research reports. Royal Bank of Canada reduced their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a "sector perform" rating for the company in a research report on Friday, November 15th. JMP Securities restated a "market outperform" rating and set a $18.00 target price on shares of Inovio Pharmaceuticals in a report on Friday. Finally, Oppenheimer dropped their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an "outperform" rating on the stock in a report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Inovio Pharmaceuticals has a consensus rating of "Hold" and an average target price of $12.40.

Inovio Pharmaceuticals Stock Down 4.0 %

INO stock traded down $0.08 during trading on Monday, reaching $1.90. 303,990 shares of the company's stock were exchanged, compared to its average volume of 1,689,988. Inovio Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $14.75. The company's fifty day moving average price is $3.42 and its 200-day moving average price is $6.10. The firm has a market cap of $49.59 million, a PE ratio of -0.91 and a beta of 0.84.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in Inovio Pharmaceuticals by 6.7% in the third quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company's stock valued at $3,594,000 after purchasing an additional 38,833 shares in the last quarter. Barclays PLC lifted its holdings in shares of Inovio Pharmaceuticals by 282.6% during the 3rd quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company's stock valued at $197,000 after buying an additional 25,116 shares during the last quarter. FMR LLC raised its position in Inovio Pharmaceuticals by 370.1% during the third quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company's stock valued at $158,000 after acquiring an additional 21,462 shares in the last quarter. State Street Corp lifted its stake in Inovio Pharmaceuticals by 11.7% in the third quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company's stock valued at $2,836,000 after acquiring an additional 51,414 shares during the last quarter. Finally, American Century Companies Inc. grew its position in Inovio Pharmaceuticals by 62.2% in the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company's stock worth $255,000 after acquiring an additional 12,100 shares in the last quarter. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.